gracecast 2020 - new tkis for stage iv non small cell lung cancer mutations with dr. jared weiss
Published 4 years ago • 42 plays • Length 5:46Download video MP4
Download video MP3
Similar videos
-
10:19
gracecast- asco lung 2020- new potential treatments for met and ret positive nsclc capmatinib-tabrec
-
9:19
gracecast-004_lung-cancer_antiangiogenesis in first line nsclc
-
18:14
gracecast-095_lung-cancer_highlights 2011: question and answer session with dr. jared weiss
-
10:39
gracecast - lcvl - can patients with an egfr mutation-positive advanced nsclc benefit from immunothe
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
6:52
gracecast - lcvl - leading treatment options for patients with low or negative tumor pd-l1 expressio
-
1:54
q&a: first line tki - patient with stage iv & no brain mets - targeted therapies in lung cancer 2023
-
6:38
gracecastuc-005 - the topical study: is rash a predictor of benefit with egfr inhibitor therapy?
-
9:26
gracecast - lcvl - which patients with advanced nsclc are good candidates for first line immunothera
-
3:06
grace targeted therapies lung cancer 2021 - tki plus chemotherapy as a firstline treatment in ros1?
-
3:51
targeted therapies forum, episode 8: detecting tki resistance with liquid biopsy
-
7:24
2020 ttf egfr session qa panel does progression always occur on osimertinib (tagrisso)?
-
25:07
gracecast-101_lung-cancer_mm in lc pt6: dr. goss on incorporating markers across a hc system
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
13:26
gracecast-012_social-work-and-coping_leah de roulet part 2
-
4:02
ros1 nsclc: chemotherapy and immunotherapy -
-
2:02
grace targeted therapies lung cancer 2021 - second line ros1 medication off-label